212-681-1575
Apr

20

Mesothelioma Patients Hopeful After Anti-Cancer Dr...

Posted by

Label: Mesothelioma


In Dec. 2015 the U.S. Food and Drug Administration approved Alecensa (alectinib) for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in patients who have progressed on or are intolerant to Xalkori (crizotinib). Now, results from a

Read Full Story

Want Specific topic updates?